Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tezepelumab by Amgen for Chronic Urticaria Or Hives: Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData,...
Tezepelumab by Amgen for Eosinophilic Esophagitis: Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase III for Eosinophilic Esophagitis. According to GlobalData, Phase III...
Tezepelumab by Amgen for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to...
Tezepelumab by Amgen for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Granulomatosis with Polyangiitis (Wegener's Granulomatosis). According to...
Tezepelumab by Amgen for Cat Allergy: Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Cat Allergy. According to GlobalData, Phase II...
Tezepelumab by Amgen for Churg-Strauss Syndrome: Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Churg-Strauss Syndrome. According to GlobalData, Phase II...